Numinus Wellness Inc. congratulates MAPP1 trial study team on announcement of results from the Phase 3 randomized clinical trial of MDMA-assisted therapy for the treatment of severe post-traumatic stress disorder (PTSD)
Numinus Wellness congratulates study team on announcement of results from Phase 3 randomized clinical trial of MDMA-assisted therapy for treatment of severe PTSD The trial, which involved 90 participants with chronic PTSD, demonstrated that 88% of participants who received three controlled and supervised MDMA-assisted therapy sessions experienced a clinically significant reduction in symptoms, with 67% no longer qualifying for PTSD diagnosis in comparison to 32% of participants randomized to placebo The results, published in the peer-reviewed medical journal Nature Medicine, pr...